 |
2 Products |  |
13 Diseases | | 2 Products |
|
0 Trials |  |
3 News |  |
- ||| pegylated epoetin alfa (YPEG-rhEPO) / BioGeneric Pharma, Xiamen Amoytop Biotech
Trial completion, Trial completion date, Trial primary completion date: A Study of YPEG-rhEPO in Patients Suffered From Anemia Due to Chronic Kidney Disease (clinicaltrials.gov) - Dec 16, 2022
P2, N=60, Completed, Sponsor: Xiamen Amoytop Biotech Co., Ltd.
Recruiting --> Completed | Trial completion date: Jun 2022 --> Jan 2022 | Trial primary completion date: Jun 2022 --> Jan 2022
- |||| pegylated epoetin alfa (YPEG-rhEPO) / BioGeneric Pharma, Xiamen Amoytop Biotech
New P2 trial: A Study of YPEG-rhEPO in Patients Suffered From Anemia Due to Chronic Kidney Disease (clinicaltrials.gov) - May 12, 2021
P2, N=60, Recruiting, Sponsor: Xiamen Amoytop Biotech Co., Ltd.
- | Y-PEG IFN- ? 2a / Xiamen Amoytop Biotech, BioGeneric Pharma
Trial completion: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Assessment of Ypeginterferon Alfa-2a in Healthy Subjects (clinicaltrials.gov) - Jan 29, 2012
P1, N=39, Completed, Sponsor: Xiamen Amoytop Biotech Co., Ltd.
Recruiting --> Completed | Trial completion date: Jun 2022 --> Jan 2022 | Trial primary completion date: Jun 2022 --> Jan 2022 Recruiting --> Completed